Skip to main content
SpringerLink
Log in

Zukunft und Grenzen der medikamentösen Therapie kardialer Erkrankungen

  • Conference paper
Wohin steuert die Medizin?

  • 20 Accesses

Zusammenfassung

Entwicklungen und Probleme der medikamentösen Therapie kardialer Erkrankungen sollen im folgenden diskutiert und sich abzeichnende neue Möglichkeiten besprochen werden. Therapeutische Fortschritte bei der Behandlung kardialer Erkrankungen orientieren sich an bestimmten Therapiezielen.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Beyerle A, Reiniger G, Rudolph W (1986) Ausgeprägter antianginöser und antiischämischer Effekt unter Langzeitbehandlung mit Molsidomin: Kein Anhalt für Toleranzentwicklung. Z Kardiol 75:93

    Google Scholar 

  • Blasini R, Reiniger G, Brügmann U, Rudolph W (1984) Vermeidung einer Toleranzentwicklung unter Isosorbiddinitrat durch Intervalltherapie. Herz 9:166–170

    PubMed  CAS  Google Scholar 

  • CASS Principal Investigators (1983) Coronary artery surgery study (CASS): A randomized trial of coronary artery bypass surgery. Circulation 68:939–950

    Article  Google Scholar 

  • Chesebro JH, Knatterud G, Roberts R et al (1987) Thrombolysis in myocardial infarction (TIMI). Trial, phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation 76:142–254

    Article  PubMed  CAS  Google Scholar 

  • Cohn JN, Archibald DG, Ziesche S et al. (1986) Effect of vasodilatator therapy on mortality in chronic congestive heart failure: Results of a Veterans Administration Cooperative Study. N Engl J Med 314:1547–1552

    Article  PubMed  CAS  Google Scholar 

  • CONSENSUS Trial Study Group (1987) Effects of enalapril in mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316:1429–1435

    Article  Google Scholar 

  • Frey AW, Brose W, Flachenecker G, Theisen K (1988) Stumme Myokardischämie im Langzeit-EKG: Ist der Standard der American Heart Association für die ST-Segment-Analyse ausreichend? Z Kardiol 77:110–114

    PubMed  CAS  Google Scholar 

  • Gottlieb SO, Weisfeldt ML, Quyang P et al. (1986) Silent ischemia as a marker for early unfavourable outcomes in patients with unstable angina. N Engl J Med 314:1214–1219

    Article  PubMed  CAS  Google Scholar 

  • Gruppo Ilaliano per lo Studio della Streptochinasi nell Infarcto Miocardico (GISSI) (1986) Effectiveness of intravenous thrombolytic treatment in the acute myocardial infarction. Lancet 1:397

    Google Scholar 

  • HINT Research Group (1987) Report of the Holland interuniversity Nifedipine Metoprolol trial (HINT) research group: Early treatment of unstable angina in the coronary care unit: A randomized, double blind, placebo controlled comparison of recurrent ischemia in patients treated with nifedipine or metoprolol or both. Br Heart J 56:400–413

    Google Scholar 

  • Hollenstein U, Blümchen G (1986) Die medikamentöse Therapie der koronaren Herzerkrankung. JAMA 7/8:524–526 (dt. Ausgabe)

    Google Scholar 

  • ISIS Collaborative Group (1988) Results of a large randomized trial of intravenous streptokinase and oral aspirin in acute myocardial infarction ISIS 2. JACC 112:232 A

    Google Scholar 

  • Jahrmärker H, Heimspoth VH, Loew D, Rietbrock N, Kubin S (1988) Herz-und Kreislauferkrankungen. Vieweg & Sohn, Braunschweig Wiesbaden

    Google Scholar 

  • Kenedy P (1985) Intraindividuelle Dosis-Wirkungsbeziehung von Elantan long. In: Borchard U, Raffleibeul W, Schrey N (Hrsg) Mononitrat. Wolf, München, pp 108–115

    Google Scholar 

  • Lewis H, Davis J, Archibald D et al. (1983) Protective effects of aspirin against myocardial infarction and death in man with unstable angina. N Engl J Med 309:396–403

    Article  PubMed  Google Scholar 

  • Lorenz RL, Weber M, Kotzur J, Theisen K, Schacky CV, Meister W, Reichardt B, Weber PC (1984) Improved aortocoronary bypass patency by low-dose aspirin (100 mg daily). Lancet 1:1261–1264

    Article  PubMed  CAS  Google Scholar 

  • MIAMI Trial Study Group (1985) Metoprolol in acute myocardial infarction (MIAMI). A randomized placebo-controlled international trial. Eur Heart J 6:199–226

    Google Scholar 

  • Moss AJ and the Multicenter Diltiazem Post-Infaction Research Group (1988) Long-term effect of diltiazem on mortality and reinfarction after myocardial infarction — the MDPIT study. JACC 11/2:27 A

    Google Scholar 

  • MRFIT, Multiple Risk Factor Invention Trial Research Group (1985) Exercise electrocardiogram and coronary heart disease mortality. Am J Cardiol 55:15

    Google Scholar 

  • Mulrow CD, Feussner JR, Velez R (1984) Reevaluation of digitalis efficacy. Ann Int Med 101:113–117

    PubMed  CAS  Google Scholar 

  • Norwegian Multicenter Study Group (1981) Imolol study. Timolol induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 305:801–807

    Google Scholar 

  • Relman AS (1988) Aspirin for the primary prevention of myocardial infarction. N Engl J Med 318:245–246

    Article  PubMed  CAS  Google Scholar 

  • Rudolph W, Dirschinder J, Kraus F (1986) Medikamentöse Behandlung der Angina pectoris. Med Welt 37:431–437

    Google Scholar 

  • Silber S (1986) Wann ist ein Patient mit koronarer Herzerkrankung optimal behandelt? Internist 27:525–540

    PubMed  CAS  Google Scholar 

  • Silber S, Vogler A, Theisen K (1986a) Equal anti-ischemic properties of isosorbide dinitrate plus verapamil and isosorbide dinitrate plus propranolol. A randomized, double-blind and cross-over study. Z Kardiol [Suppl. 3] 75:100–105

    PubMed  Google Scholar 

  • Silber S, Vogler A, Theisen K (1986b) Problems of anti-ischemic drug therapy in patients with insufficient nitrate response. J Am Coll 7:28 A

    Google Scholar 

  • Silber S, Vogler AC, Krause KH, Vogel M, Theissen K (1987) Induction and circumvention of nitrate tolerance applying different dosage intervals. Am J Med 83:860–870

    Article  PubMed  CAS  Google Scholar 

  • Solis E, Kaye MP (1986) The Registry of the International Society for Heart Transplantation. Third Official Report — June 1986. Heart Transpl 5:2

    CAS  Google Scholar 

  • Steering Committee of the Physicians’ Health Study Research Group (1988) Preliminary report: Findings from the aspirin component of the ongoing physicians’ health study. N Engl J Med 318:262–264

    Article  Google Scholar 

  • Subramanian VB, Bowles MJ, Davis A, Raftery EB (1982) Combined therapy with verapamil and propranolol in chronic stable angina. Am J Cardiol 49:125–132

    Article  PubMed  CAS  Google Scholar 

  • Taylor SH (1982) Promises and disapointment of vasodilatator treatment of chronic heart failure. In: Just H, Bussmann WD (eds) Vasodilatators and chronic heart failure. Springer, Berlin Heidelberg New York Tokyo, p. 83

    Google Scholar 

  • Theisen K (1985) Welche Extrasystolen müssen behandelt werden? Schwerpunktmed 8:19–27

    Google Scholar 

  • Theisen K, Angermann C, Silber S, Weber M, Jahrmärker H (1986) Überflüssige kardiologische Diagnostik. Internist 27:552–565

    PubMed  CAS  Google Scholar 

  • Theisen K, Angermann C, Kemkes BM (1988) Indikation zur Herztransplantation: Auswahlkriterien für Empfänger. In: Berghoff A (Hrsg) Kardiologische Rehabilitation 1987. Heenemann, Berlin

    Google Scholar 

  • Yacoub MH, Al-khadimi RH, Radley-Smith R (1985) Cardiac transplantation — the London experience. Z Kardiol 74:45–50

    PubMed  Google Scholar 

Download references

Authors
  1. K. Theisen
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Med. Klinik St. Irmingard, Osternacher Straße 103, D-8210, Prien am Chiemsee, Germany

    Klaus-Diethart Hüllemann

Rights and permissions

Reprints and permissions

Copyright information

© 1990 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Theisen, K. (1990). Zukunft und Grenzen der medikamentösen Therapie kardialer Erkrankungen. In: Hüllemann, KD. (eds) Wohin steuert die Medizin?. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-74428-0_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-74428-0_3

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-50762-8

  • Online ISBN: 978-3-642-74428-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation